Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans
Top Cited Papers
Open Access
- 17 March 2026
- journal article
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (3) , 102665
Abstract
No abstract availableKeywords
Funding Information
- Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen
- Bundesministerium für Forschung, Technologie und Raumfahrt
- Institute of Space and Astronautical Science
- University of California, Davis (T32 GM144303)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK139663)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK139565)
This publication has 55 references indexed in Scilit:
- Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in miceCell Metabolism, 2025
- Semaglutide‐induced weight loss improves mitochondrial energy efficiency in skeletal muscleObesity, 2025
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or ObesityJAMA Internal Medicine, 2024
- Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitusClinical Nutrition, 2024
- Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant?JAMA, 2024
- GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathwayBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2022
- A novel mouse model of hindlimb joint contracture with 3D‐printed castsJournal of Orthopaedic Research, 2022
- Sex differences in systemic bone and muscle loss following femur fracture in miceJournal of Orthopaedic Research, 2021
- Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophyJournal of Cachexia, Sarcopenia and Muscle, 2019
- Skeletal muscle atrophy during short-term disuse: Implications for age-related sarcopeniaAgeing Research Reviews, 2013